Allogene Therapeutics, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · South San Francisco, CA
ALLO chart
What traders are saying about $ALLO
Latest postsAllogene Therapeutics, Inc. news
- Allogene Therapeutics reports clinical data from RESOLUTION study
TipRanks ·
- Allogene Therapeutics, Inc. (ALLO) Stock Price, News, Quote & History
Yahoo! Finance Canada ·
- Allogene Therapeutics Reports First Clinical Data from Phase 1 RESOLUTION Study of ALLO-329 in Autoimmune Disease
Yahoo Finance ·
- RBC Capital Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9
富途牛牛 ·
- Allogene Therapeutics (ALLO) Advances ALPHA3 Trial with Strong A
GuruFocus ·
- Allogene (ALLO) Q3 2026 Earnings Call Transcript
fool.com ·
- Allogene Therapeutics 3Q 2026: Revenue $0, EPS ($0.15) — 10-Q Summary
TradingView ·
- Allogene Therapeutics Inc (ALLO) (Q3 2026) Earnings Call Highlights: Alpha 3 Momentum Builds as ...
Yahoo Finance ·
- Allogene Therapeutics Q3 Earnings Call Highlights
marketbeat.com ·
- Allogene Therapeutics, Inc. reports results for the quarter ended September 30 - Earnings Summary
TradingView ·
- Allogene Therapeutics Reports Q3 2026 Net Loss of $50.4 Million, EPS Matches Estimate at -$0.15
GuruFocus ·
- Allogene Therapeutics Q3 2026 Earnings Call Transcript
Benzinga ·
Allogene Therapeutics, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $0 | $22,000 | $95,000 | $156,000 |
| Net income | -$190.9M | -$257.6M | -$327.3M | -$340.4M |
| Diluted EPS | $-0.87 | $-1.32 | $-2.09 | $-2.38 |
| Total assets (year end) | $415.9M | $548.7M | $642.8M | $821.6M |
| Cash and equivalents (year end) | $51.7M | $75.2M | $83.2M | $61.9M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Allogene Therapeutics, Inc.
- Ticker
- ALLO (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Fiscal year end
- December 31
- SEC CIK
- 1737287
Frequently asked questions
What exchange is Allogene Therapeutics, Inc. listed on?
Allogene Therapeutics, Inc. trades on the Nasdaq under the ticker symbol ALLO.
What industry is Allogene Therapeutics, Inc. in?
Allogene Therapeutics, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Allogene Therapeutics, Inc. headquartered?
Allogene Therapeutics, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Allogene Therapeutics, Inc.'s fiscal year end?
Allogene Therapeutics, Inc.'s fiscal year ends on December 31.
How much revenue did Allogene Therapeutics, Inc. report?
Allogene Therapeutics, Inc. reported $0 in revenue for calendar year 2025, according to its SEC filings.